This MedLibrary.org supplementary page on Formoterol is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Formoterol
|
|
| Systematic (IUPAC) name | |
| N-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl) propan-2-ylamino]ethyl] phenyl]formamide | |
| Identifiers | |
| CAS number | |
| ATC code | R03 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C19H24N2O4 |
| Mol. mass | 344.405 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 61–64% |
| Metabolism | Hepatic demethylation and glucuronidation (CYP2D6, CYP2C19, CYP2C9 and CYP2A6 involved) |
| Half life | 10 hours |
| Excretion | Renal and fecal |
| Therapeutic considerations | |
| Pregnancy cat. | |
| Legal status | |
| Routes | Oral, Inhalation |
Formoterol (INN) or eformoterol (former BAN) is a long-acting β2-agonist used in the management of asthma and/or chronic obstructive pulmonary disease (COPD). It is marketed in four forms: a dry-powder inhaler (DPI), metered dose inhaler (MDI), an oral tablet, and as an inhalation solution, under various trade names including Foradil/Foradile (Novartis), Oxis (AstraZeneca), Atock (Astellas) and Perforomist (Dey).
Formoterol is a long-acting β2 agonist (LABA), which has an extended duration of action (up to 12 hours) compared to short-acting β2 agonists such as salbutamol, which have are effective for 4–6 hours. LABAs such as formoterol are used as "symptom controllers" to supplement prophylactic corticosteroid therapy (e.g. fluticasone). A "reliever" short-acting β2 agonist (e.g. salbutamol) is still required, since LABAs are not recommended for the treatment of acute asthma.
Mechanism of action
Inhaled formoterol works like other β2-agonists, causing bronchodilatation by relaxing the smooth muscle in the airway so as to treat the exacerbation of asthma. The long duration of formoterol action occurs because the formoterol molecules initially diffuse into the plasma membrane of the lung cells, and then are slowly released back outside, where they can come into contact with β2 adrenergic receptors. Formoterol has been demonstrated to have a faster onset of action than salmeterol as a result of lower lipophilicity, and has also been demonstrated to be more potent - a 12 µg dose of formoterol has been demonstrated to be equivalent to a 50 µg dose of salmeterol.
Safety
In November 2005, the American FDA released a health advisory[1], alerting the public to findings that show the use of long-acting β2-agonists could lead to a worsening of symptoms.
Currently available long-acting β2-agonists include salmeterol, formoterol, bambuterol, and sustained-release oral salbutamol. Combinations of inhaled steroids and long-acting bronchodilators are becoming more widespread – combination preparations include fluticasone/salmeterol and budesonide/formoterol.
See also
|
|||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 1 September 2008, at 17:31.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Formoterol".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.